Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
暂无分享,去创建一个
J. Connors | S. Ansell | A. Younes | M. Fanale | D. Huebner | Steven I. Park | N. Hunder | M. O'Meara
[1] Stephane Chauvie,et al. International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.
[2] R. Advani,et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Scott E Smith,et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Amthauer,et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial , 2012, The Lancet.
[5] C. Poirot,et al. Management of fertility in patients treated for Hodgkin’s lymphoma , 2011, Haematologica.
[6] A. Rossi,et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. , 2011, The New England journal of medicine.
[7] J. Radford,et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[8] A. Pettitt,et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] F. Angrilli,et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Advani,et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Rowe,et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. , 2007, Blood.
[14] P. Gobbi,et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] T. Habermann,et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Connors,et al. State-of-the-art therapeutics: Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Niedzwiecki,et al. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Connors,et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Dirk Hasenclever,et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.
[20] D. Winfield,et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.
[21] J. Smith,et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. , 1972, Annals of internal medicine.